10.3275/7141 [DOI] [PubMed] [Google Scholar] 137.Rasmusson B, Feldt-Rasmussen U, Hegedus L, Perrild H, Bech K, Hoier-Madsen M
10.3390/cancers16020244 119
Lakshmanan, P
for obesity, 17% require a behavior change program as a prerequisite for coverage 94% of all respondents believe utilization will increase over the next three years Navigating GLP-1, Diabetes and Obesity Costs Without getting into efficacy of individual drugs, as a class they improve glycemic control for patients with T2D and reduce body mass index (BMI) between 7% and 16% in a year (+/- a few months)
Wyatt, director of the Section of Sleep Disorders and Sleep-Wake Research at Rush University Medical Center in Chicago
cardiotropic nanoparticles or peptide-guided prodrugs) are being explored to confine drug action to the heart, thereby improving safety and efficacy [374]